PreciseDx®, a NYC-based leader in oncology diagnostics, raised $20.7M in Series B funding.

The investment round was guided by Eventide Asset Management, with Labcorp, Quest Diagnostics, and GenHenn Capital Venture also participating alongside existing investors.

The funds will spearhead the commercialization efforts for PreciseBreast™, a risk assessment tool that leverages the company's AI-driven Morphology Feature Array® for precise disease insights.

PreciseDx aims to revolutionize cancer diagnostics with two successful validation studies, CLIA Standard approval, CLEP NYSDOH review, and strategic partnerships with UCLA, COTA, and more.

This funding marks a significant milestone, enabling further innovative advancements in AI-driven cancer care solutions.